Similar articles for PMID: 27859136

Year	Number of Results
1994	1
1995	1
1998	2
1999	2
2004	1
2005	1
2006	2
2007	1
2008	3
2009	2
2010	2
2011	7
2012	10
2013	13
2014	16
2015	18
2016	22
2017	15
2018	11
2019	15
2020	8
2021	12
2022	10
2023	3
2024	0

1

KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.

Nagy Á, Pongor LS, Szabó A, Santarpia M, Győrffy B. Nagy Á, et al. Int J Cancer. 2017 Feb 15;140(4):930-937. doi: 10.1002/ijc.30509. Epub 2016 Nov 23. Int J Cancer. 2017. PMID: 27859136 Free PMC article.

2

Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.

Chakrabarti G. Chakrabarti G. Radiat Oncol. 2015 Jul 16;10:145. doi: 10.1186/s13014-015-0457-x. Radiat Oncol. 2015. PMID: 26173780 Free PMC article.

3

Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.

Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Shukla S, et al. J Natl Cancer Inst. 2016 Oct 5;109(1):djw200. doi: 10.1093/jnci/djw200. Print 2017 Jan. J Natl Cancer Inst. 2016. PMID: 27707839 Free PMC article.

4

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.

Li B, Cui Y, Diehn M, Li R. Li B, et al. JAMA Oncol. 2017 Nov 1;3(11):1529-1537. doi: 10.1001/jamaoncol.2017.1609. JAMA Oncol. 2017. PMID: 28687838 Free PMC article.

5

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L, Besse B. Facchinetti F, et al. Lung Cancer. 2017 Oct;112:62-68. doi: 10.1016/j.lungcan.2017.08.002. Epub 2017 Aug 7. Lung Cancer. 2017. PMID: 29191602

6

A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.

Zuo S, Wei M, Zhang H, Chen A, Wu J, Wei J, Dong J. Zuo S, et al. J Transl Med. 2019 May 14;17(1):152. doi: 10.1186/s12967-019-1899-y. J Transl Med. 2019. PMID: 31088477 Free PMC article.

7

KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.

Liu YZ, Yang H, Cao J, Jiang YY, Hao JJ, Xu X, Cai Y, Wang MR. Liu YZ, et al. Sci Rep. 2016 Apr 21;6:24786. doi: 10.1038/srep24786. Sci Rep. 2016. PMID: 27098511 Free PMC article.

8

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.

Kim JH, Kim HS, Kim BJ. Kim JH, et al. Oncotarget. 2017 Jul 18;8(29):48248-48252. doi: 10.18632/oncotarget.17594. Oncotarget. 2017. PMID: 28525386 Free PMC article. Review.

9

Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.

Suzuki M, Shigematsu H, Iizasa T, Hiroshima K, Nakatani Y, Minna JD, Gazdar AF, Fujisawa T. Suzuki M, et al. Cancer. 2006 May 15;106(10):2200-7. doi: 10.1002/cncr.21853. Cancer. 2006. PMID: 16598760 Free article.

10

Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.

Planck M, Isaksson S, Veerla S, Staaf J. Planck M, et al. Clin Cancer Res. 2013 Sep 15;19(18):5116-26. doi: 10.1158/1078-0432.CCR-13-0928. Epub 2013 Aug 12. Clin Cancer Res. 2013. PMID: 23938291

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

155 results

Results by year